Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II DOS regimen in HER2-negative unresectable metastatic gastric cancer
jRCTs061180095Phase 2Completed
- Start
- Jun 2017
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tegafur, docetaxel and oxaliplatin in gastric cancer (GC). Primary endpoints: maximum tolerated dose, dose-limiting toxicities and 2 more. Started Jun 2017; status: completed.
02
Drugs
tegafurdocetaxeloxaliplatin
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on jRCTs061180095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs061180095.